Summary
DexCom, Inc. (DXCM) filed its Form 10-Q for the quarterly period ended June 30, 2010, reporting significant revenue growth in its core product segment. Product revenue more than doubled year-over-year for both the three-month and six-month periods, indicating increasing market adoption of its continuous glucose monitoring systems. This top-line growth is encouraging, though the company continues to operate at a net loss, which is typical for companies in this development and commercialization stage. Financially, DexCom saw an increase in cash and cash equivalents, largely driven by financing activities including a follow-on public offering in January 2010. However, the company also reported a substantial loss on the extinguishment of convertible debt due to exchanges made during the period, impacting the bottom line. The company's liquidity appears sufficient for the next twelve months, but future funding needs remain a consideration as it continues to invest in research, development, and commercialization efforts. Investors should monitor the company's ability to achieve profitability while managing its ongoing investment in innovation and market expansion.
Financial Highlights
22 data points| Revenue | $11.79M |
| Cost of Revenue | $7.27M |
| Gross Profit | $4.52M |
| R&D Expenses | $5.42M |
| SG&A Expenses | $10.36M |
| Operating Expenses | $15.79M |
| Operating Income | -$11.27M |
| Interest Expense | $197K |
| Net Income | -$11.69M |
| EPS (Basic) | $-0.05 |
Key Highlights
- 1Product revenue increased significantly year-over-year, demonstrating strong market demand for DexCom's continuous glucose monitoring systems.
- 2The company reported an increase in operating expenses, particularly in Research & Development and Selling, General & Administrative, reflecting continued investment in product development and commercialization.
- 3DexCom completed significant exchanges of its convertible notes for common stock, reducing its long-term debt but also resulting in a substantial loss on extinguishment of debt.
- 4Cash and cash equivalents increased, bolstered by proceeds from a follow-on public offering in January 2010, contributing to a positive working capital position.
- 5The company continues to generate net losses, consistent with its growth phase, with an accumulated deficit of $323.2 million as of June 30, 2010.
- 6DexCom is actively involved in patent litigation with Abbott Diabetes Care, which presents an ongoing risk to the company.
- 7The company is pursuing regulatory approvals for new products and indications, including an in-hospital glucose monitoring system and potential pediatric and gestational diabetes indications for its ambulatory products.